Elevated neutrophil-to-lymphocyte ratio predicts brain metastasis risk in lung cancer patientsCould a simple blood test help find who is most at risk for brain metastasis from lung cancer?

A systematic review and meta-analysis assessed the associations of neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and lymphocyte-to-monocyte ratio (LMR) with the risk of brain metastasis from lung cancer. The analysis included data from 3,643 participants with lung cancer. No specific study design details or follow-up durations were reported for the individual studies contributing to this synthesis.

The primary outcome measured was the risk of developing brain metastasis. Results indicated that an elevated NLR served as an independent risk factor for this outcome. The pooled odds ratio was 1.61, with a 95% confidence interval of 1.27 to 2.05. No significant associations were reported for PLR or LMR in the provided results.

Safety and tolerability data were not reported, as adverse events, discontinuations, and serious adverse events were not captured in the input data. The study phase was not reported, and funding or conflicts of interest were not specified. Key limitations include the lack of reported certainty assessments and the potential for heterogeneity among the included observational studies.

The practice relevance suggests offering evidence-based support for the early clinical identification of high-risk patients. However, clinicians should note that these findings derive from observational data where causality cannot be established. The evidence supports using NLR as a potential marker but does not confirm it as a definitive diagnostic tool for brain metastasis risk.